Clinical trials: Psychotic Disorder
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Delirium, Agitated Behavior
Trial of Safety Nets In Hospitalized Patients
This study compared standard hospital restraints to a newer safety net restraint system to compare them for acceptability, tolerance, duration of restrain, length of stay in the hospital, and satisfaction of MD, nurse, and…
- Conditions
- Delirium, Agitated Behavior, Alcohol Withdrawl, Acute Confusional State
- Trial name
- NCT00409370
- Testing
- SOMA safe enclosure
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Griffin Hospital
Psychotic Disorder
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat with antipsychotics, which are mostly effective for positive symptoms.
- Trial name
- DROP (NCT04140773)
- Testing
- D-serine
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Dragos Inta
Psychotic Disorders
Hormonal and Inflammatory Biomarkers and Response to Cognitive Remediation in Recent-onset Psychosis
This study aims to explore whether hormones or inflammatory markers are associated with cognitive changes following cognitive remediation therapy (CRT) in people with a recent-onset psychotic disorder.
- Trial name
- NCT04418570
- Testing
- cognitive remediation, attendance to an Early Intervention Service for Psychosis
- Volunteers
- 28 people
- Sponsor
- Corporacion Parc Tauli
Schizophrenia, Schizoaffective Disorder
Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness
This open trial will test a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social engagement in consumers with serious mental illness.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Mood Disorder, Psychotic
- Trial name
- mSITE (NCT05660070)
- Testing
- mobile Social Interaction Therapy by Exposure (mSITE)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of California, San Diego
Schizophrenia, Bipolar Disorder
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
The purpose of this study is to characterize olanzapine pharmacokinetics: the inter- and intra- subject variabilities of olanzapine pharmacokinetics; and the potential influence of patient factors such as age, weight, gender…
- Trial name
- NCT00113594
- Testing
- Olanzapine
- Where
- 17 sites in United States, Puerto Rico and 1 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
- Trial name
- NCT06504290
- Testing
- VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia)
- Where
- 4 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Early Psychosis
PSYCHE Cognitive Remediation & Social Recovery Study
This study is a pilot feasibility study embedded in the Early Intervention in Psychosis (EIP) services in Ireland. It explores the feasibility and acceptability of a combined cognitive remediation training and social recovery…
- Trial name
- NCT06032182
- Testing
- CRESTR Intervention, CRESTR Control
- Where
- 5 sites in Ireland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National University of Ireland, Galway, Ireland
Schizophrenia
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia
- Trial name
- NCT00487942
- Testing
- armodafinil
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cephalon
Schizophrenia
Social Cognition Training and Vocational Rehabilitation
Social cognition impairments, frequently encountered in Serial Mental Illness, reduce the ability to find and to keep a job. Cognitive remediation and social cognition training reduce the impact of cognitive impairments on work…
- Trial name
- REMEDEMPLOI (NCT04025905)
- Testing
- Social Cognition Training, Informations
- Where
- France
- Volunteers
- 149 people
- Sponsor
- Hôpital le Vinatier
Schizophrenia, Schizoaffective
Is Cognitive Training an Option?
The purpose of the study is to evaluate the feasibility of implementing cognitive training with 40 patients living with schizophrenia and schizoaffective disorder.
- Conditions
- Schizophrenia, Schizoaffective, Cognition
- Trial name
- NCT05352568
- Testing
- Cognitive Training
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alliant International University
Schizophrenia
Effect of Nicotine Transdermal Patch on Cognitive Function and Glycolipid Metabolism in Non-smoking Schizophrenia
Schizophrenia is a group of severe mental disorders of unknown etiology, with significant abnormalities in mental activities such as cognition, thinking, emotion, and behavior, and lead to obvious occupational and social function…
- Trial name
- NCT05301660
- Testing
- Nicotine transdermal patch
- Volunteers
- 80 people
- Sponsor
- Sir Run Run Shaw Hospital
Schizophrenia
A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone
The purpose of this research study is to measure how many of the dopamine receptors lurasidone occupies throughout the brain of patients with schizophrenia or schizoaffective disorder and over what time period the occupancy…
- Trial name
- NCT01979679
- Testing
- Lurasidone 80 mg, Lurasidone 120 mg, Lurasidone 160 mg
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, Irvine
Schizophrenia, Schizoaffective Disorder
Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging
The goal of the project is to characterize abnormalities in brain structure and function related to schizophrenia. The investigators will use advanced magnetic resonance imaging (MRI) techniques to measure the degree and…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Hallucinations
- Trial name
- NCT00288340
- Testing
- functional magnetic resonance imaging
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Schizophrenia, Cognitive Deficits
Augmentation of Working Memory Training With Transcranial Direct Current Stimulation in Patients With Schizophrenia
Cognitive impairment is a core symptom of schizophrenia and is in a large part responsible for the poor psychosocial outcome of the disorder.
- Trial name
- NCT03621540
- Testing
- active tDCS, Adaptive working memory training
- Where
- 2 sites in Germany
- Volunteers
- 37 people
- Sponsor
- University Hospital Tuebingen
Schizophrenia
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia.
- Trial name
- NCT03437668
- Testing
- WSE
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Chengappa, K.N. Roy, MD
Schizophrenia
Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.
This study will compare bifeprunox to a currently marketed medication, Zyprexa (olanzapine), with respect to the affect on weight during the treatment of outpatients with schizophrenia.
- Trial name
- NCT00380224
- Testing
- bifeprunox, olanzapine
- Where
- 67 sites in United States
- Volunteers
- 120 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Organic Brain Syndrome, Nonpsychotic, Neurocognitive Disorders
Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome
The investigators have designed an innovative proof-of-concept trial designed to provide data as to whether the treatment/rehabilitation efficacy and functional outcome of patients with organic brain syndrome are improved with…
- Conditions
- Organic Brain Syndrome, Nonpsychotic, Neurocognitive Disorders, Mental Disorder, Organic, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT02957123
- Testing
- Intranasal auto-M2-BFs
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Russian Academy of Medical Sciences
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mood Disorders, Anxiety Disorders
Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)
This study aimed to determine the feasibility and acceptability of delivering Resilience Training in multi-user virtual reality.
- Conditions
- Mood Disorders, Anxiety Disorders, Psychotic Disorders
- Trial name
- NCT06360562
- Testing
- Resilience Training
- Where
- United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital